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Key Points
• PP2A inhibition occurs
in AML by 2 different
pathways: CIP2A in
normal karyotype
patients and SETBP1
in adverse karyotype
patients.
• AKTS473 phosphoryla-
tion is a predictor of
survival, and diagnostic
levels of AKTS473 could
be a novel biomarker in
AML.
Introduction
Acute myeloid leukemia (AML) is curable with modern treatment including stem cell transplantation
(SCT) for a small proportion of patients; however, the majority of patients will die of their disease. Protein
phosphatase 2A (PP2A) is a phosphatase and a tumor suppressor, which is often inhibited in malignant
cells by the inhibitory proteins cancerous inhibitor of PP2A (CIP2A), SET, and binding protein for SET
(SETBP1), leading to abnormal proliferation and differentiation.1 High levels of CIP2A correlate with
suppressed PP2A activity and are an adverse prognostic indicator in many malignancies.2-6 CIP2A
functions by preventing PP2A-driven dephosphorylation of c-Myc, which results in stabilization.1,4,7-9
CIP2A protein is associated with increased proliferation and cellular transformation in several
malignancies,3,10,11 as well as an antiapoptotic phenotype.12 In chronic myeloid leukemia (CML),
a high CIP2A protein level is a predictor of subsequent progression to blast crisis.13 In AML,
overexpression of the SETBP1 predicts adverse outcome in elderly patients.14 SETBP1 overexpression
protects SET from protease cleavage, which results in inhibition of PP2A. However, the clinical
relevance of high CIP2A protein in AML is unknown.
AKT is a serine/threonine kinase, and constitutive activation is frequently observed in many malignacies.15-18
Activation of AKT is dependent on its phosphorylation at serine 473. AKT phosphorylation status is PP2A
dependent. CIP2A can regulate the activity of AKT.19
Methods
The levels of PP2A and network-related proteins were studied in a panel of 120 AML samples. Samples
were collected in the UK AML15 (younger patients, n 5 79, of whom 39 were normal karyotype and 40
adverse karyotype) and AML16 trials (n 5 41, aged over 60 years). Details of the trial protocols are
provided in supplemental Methods.20,21 Patients were stratified into intermediate or adverse risk, based
on cytogenetics.22 Flow cytometry was performed as previously described13 for the detection of CIP2A,
PP2Ac, PP2AY307 (to assess inactive PP2A), SET, SETBP1, c-Myc, E2F1, AKTT308 and AKTS473, and
STAT5 (for more details, see supplemental Methods). The mean fluorescence intensity (MFI) for CIP2A
protein level across all 120 patients ranged from 0 to 13.69, with an interquartile range of 1.47 to 5.11
and a median of 3. Using the same statistical approach as previously reported in CML,9 high CIP2A
patients are defined as those patients with a CIP2A MFI level $3.
Results and discussion
AML15 normal karyotype patients have higher diagnostic CIP2A protein levels than AML15 adverse
karyotype (P 5 .005) or AML16 normal karyotype (P # .001) (Figure 1A). No relationship is seen
between the CIP2A level and overall survival or relapse risk (supplemental Figure 1A-B). It was not
possible to examine the relationship between CIP2A level and remission rate as all but 1 patient entered
remission within 2 courses of treatment. However, in 51% of remitters who later relapsed, high CIP2A
was associated with inferior survival from relapse of 56 days, compared with 303 days in patients with
low CIP2A (Figure 1B). No correlation was seen between CIP2A messenger RNA levels and clinical
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outcome. Interestingly, the presence of an FLT3-ITD mutation was
associated with higher levels of CIP2A though not with mutated
NPM1 messenger RNA (P 5 .03; Figure 1C).
FLT3-ITD mutations induce constitutive tyrosine kinase activity and
confer a poor prognosis. In analyses adjusted for FLT3-ITD
mutation and censoring at SCT, the association between high
CIP2A patients and shorter survival from relapse was retained
(hazard ratio, 4.02; P 5 .04).
High CIP2A protein levels are associated with significantly higher
levels of inactive PP2A (assessed by PP2AY307), SET, SETBP1,
c-Myc, AKTS473, STAT5, and E2F1, shown in supplemental Figure 2,
panels A-G, respectively. These data suggest that a similar CIP2A/
PP2A signaling pathway exists to that previously described in CML,9
with the exception of AKTS473, which is a new association
(supplemental Figure 2).
The diagnostic level of SETBP1 protein is higher in AML15 patients
with adverse karyotype than in comparable normal karyotype
patients (P 5 .001; Figure 2A). One-third of patients had no
detectable SETBP1. All AML patients are stratified into diagnostic
SETBP1 terciles: absent (T1), intermediate (T2), and high (T3).
Patients with detectable SETBP1 protein at diagnosis (T2 and T3)
have an inferior overall survival than those in whom SETBP1 protein
was undetectable (T1) (P5 .01; Figure 2B). This association is also
shown within the younger patients with adverse karyotype (P5 .02;
Figure 2C), in whom a relationship between detectable SETBP1
and inferior relapse-free survival is also seen (P 5 .02; Figure 2D).
High SETBP1 was associated with high SET levels as it protects
SET from degradation and inactivates PP2A (elevated levels of
PP2AY307; P 5 .01). High SETBP1 was associated with elevated
CIP2A (P5 .02) suggesting that PP2A inhibition occurs by multiple
methods. c-Myc and c-MycS62 levels were also elevated (P# .001),
consistent with stabilization of c-Myc in the presence of PP2A
inhibition. Additionally, AKT was elevated and activated, as
evidenced by elevated AKTS473 (P 5 .01) and AKTT308 levels
(P , .0001) (supplemental Figure 3A-G). No difference in the level
of E2F1 was observed in adverse karyotype patients, unlike that
observed in normal karyotype patients when stratified by CIP2A.
These data imply that the mode of PP2A inhibition by SETBP1 is
different to the previously described CIP2A/c-Myc/E2F1 inhibition
in normal karyotype and CML patients.9
AKT is a substrate for PP2A and its phosphorylation status is a
marker of PP2A activity. No relationship was seen between
AKTT308 phosphorylation and outcome. AKTS473 phosphoryla-
tion was significantly associated with both raised CIP2A and
CIP2A
MF
I
FLT3 normal FLT3-ITD
0
5
10
15 p=0.03
C
CIP2A
A
MF
I
AML15
normal
AML15
advserse
AML16
normal
0
2
4
6 p=0.001
*
*
*
p=0.005
Months from relapse
%
 a
liv
e
AML15: Survival from relapse (excluding SCT)
B
0
At risk:
Below 3
3 or above
10
10
9
4
2
1
1
0
0
0
0
25
50
75
Below 3
3 or above
No.
Events
No.
Patients
410
2P = 0.07
710
0% 0%
Below 3
3 or above
100
3 6 9 12
Figure 1. High CIP2A-expressing patients have inferior survival from relapse. (A) Diagnostic CIP2A protein level in 120 AML patients. AML15 are younger patients;
AML16 are older patients. AML15 normal karyotype (N 5 39); AML15 adverse karyotype (n 5 40); and AML16 normal karyotype (N 5 41). (B) AML15 normal karyotype patients
stratified by diagnostic CIP2A level. P values are only significant where shown. Survival from relapse. The numbers of assessable cases are shown below each plot. The log-rank
test was used for Kaplan-Meier estimates. (C) CIP2A level stratified by FLT3-ITD mutation status. *Denotes statistical significance when compared to normal MNC cells.
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SETBP1 (P 5 .003 and P 5 .03; supplemental Figures 2E and
3H). PP2A inactivity was significantly correlated with AKT
activation (P# .0001; Figure 2E). High AKTS473 phosphorylation
was significantly associated with poorer overall survival in young
adverse karyotype patients (P 5 .05; Figure 2F). These data
suggest that PP2A inhibition is a common event in AML and
can occur by 2 mechanisms. CIP2A-mediated inhibition of PP2A
is seen in normal karyotype patients whereas SETBP1-mediated
inhibition of PP2A is observed in adverse karyotype patients.
Both CIP2A and SETBP1 act to inhibit PP2A, and AKTS473
phosphorylation may therefore be acting as a readout of PP2A
inhibition (Figure 2G).
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Figure 2. Patients with detectable SETBP1 protein at diagnosis have inferior overall survival. (A) SETBP1 protein expression is significantly elevated in younger
AML patients with adverse karyotype (P 5 .001; Mann-Whitney U test). Error bars are standard error of mean. (B) Kaplan-Meier estimates for overall survival in all patients.
All AML patients are stratified into diagnostic SETBP1 terciles: absent (T1), intermediate (T2), and high (T3). (C) Young adverse patients. (D) Relapse-free survival for younger
adverse AML patients, stratified by the SETBP1 level at diagnosis. The numbers of assessable cases are shown below each plot. (E) High AKTS473 level is associated with
inferior overall survival. (F) Kaplan-Meier estimates for overall survival for young adverse AML patients stratified by quartiles according to the AKTS473 level at diagnosis. High
AKTS473 level is associated with inferior overall survival (P 5 .05; log-rank test). (G) Suggested model of PP2A inhibition in AML. In normal karyotype patients, PP2A is
inhibited predominately by CIP2A whereas in adverse-risk patients, SETBP1 inhibition dominates. PP2A inhibition from either source results in high levels of AKTS473. *Denotes
statistical significance when compared to normal MNC cells. CR, complete remission.
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Multivariable analysis using Cox regression was used to find the
most important predictors of outcome in all 120 patients. Factors
included the following: age, trial (AML15 vs AML16), diagnostic
cytogenetic category, presentation white blood cell count, second-
ary leukemia or the presence of FLT3-ITD, plus the PP2A network
proteins: total PP2A, PP2AY307, CIP2A, SET, SETBP1, c-Myc,
c-MycS62, STAT5, AKTT308, and AKTS473. The level of AKTS473 was
the third most significant factor in analysis of survival censored at
SCT, after age and cytogenetic category; it was therefore the most
powerful molecular marker. Multivariate analysis also showed that
the CIP2A diagnostic protein level was a stronger predictor than
FLT3-ITD mutation at predicting survival from relapse (hazard ratio,
4.02; P 5 .04).
In summary, we demonstrate 3 principal findings. First, high CIP2A
protein levels correlate with poor survival from relapse in normal
karyotype patients. CIP2A protein level strongly correlates with
FLT3-ITD mutation. Second, SETBP1 is higher in younger patients
with adverse karyotype, and detectable levels correlate with poor
overall survival. Third, the phosphorylation status of AKT may be a
useful novel biomarker for outcome in AML. This could be assessed
as part of a diagnostic flow cytometry antibody panel, although this
would require optimization/validation before being used in a routine
clinical setting. Interestingly, a specific AKT inhibitor has been
reported to inhibit cell proliferation and clonogenic properties and to
induce apoptosis in AML cells with high-risk cytogenetics.23 Together
with the present findings, this suggests that AKT phosphorylation
status may represent a novel therapeutic target in high-risk AML and
should be tested prospectively as part of a clinical trial.
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